Coenzyme A
Research reviewed: Up until 03/2026
Coenzyme A (Pantethine) is a dietary supplement with 8 published peer-reviewed studies involving 620 participants, researched for Cholesterol & Lipid Management, Cardiovascular Health, Pediatric & Special Populations.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Cholesterol & Lipid Management
ModerateCardiovascular Health
StrongPediatric & Special Populations
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Cholesterol & Lipid Management
To evaluate pantethine supplementation on lipid profile in adults with moderate hypercholesterolaemia
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate pantethine supplementation on lipid profile in adults with moderate hypercholesterolaemia
Dose
900 mg/day pantethine
Participants
120 adults with moderate hypercholesterolaemia
Duration
16 weeks
Results
LDL reduced by 11.1% (p<0.001), total cholesterol by 8.4%, and triglycerides by 14.2%. HDL increased by 6.1%. No changes in liver or renal function.
How They Measured It
Total cholesterol, LDL, HDL, triglycerides, ApoB
To assess pantethine on lipids in subjects with low-to-moderate cardiovascular disease risk
Study Type
Randomised, double-blind, placebo-controlled, crossover
Purpose
To assess pantethine on lipids in subjects with low-to-moderate cardiovascular disease risk
Dose
600 mg/day pantethine
Participants
32 adults with low-to-moderate CVD risk
Duration
8 weeks per arm
Results
Significant reductions in total cholesterol (-6.5%), LDL (-8.0%), non-HDL (-10.4%), and ApoB (-8.6%) vs placebo. Safe and well-tolerated.
How They Measured It
Fasting lipid panel, ApoB, LDL particle number
To review the clinical evidence for pantethine on lipid profiles
Study Type
Systematic review and meta-analysis
Purpose
To review the clinical evidence for pantethine on lipid profiles
Dose
600-1200 mg/day
Participants
Meta-analysis of 28 studies
Duration
4-18 months
Results
Consistent reductions in total cholesterol and LDL. Triglyceride reductions particularly notable (average 14-21%). Good safety profile. Suitable for statin-intolerant patients.
How They Measured It
Lipid panel across available RCTs
Cardiovascular Health
To evaluate pantethine on platelet function and coagulation parameters
Study Type
Randomised, placebo-controlled
Purpose
To evaluate pantethine on platelet function and coagulation parameters
Dose
900 mg/day pantethine
Participants
40 patients with hyperlipidaemia
Duration
3 months
Results
Significant reduction in platelet aggregation and thromboxane B2 levels. Anti-thrombotic effects observed. LDL oxidation reduced by 17%.
How They Measured It
Platelet aggregation, ADP-induced aggregation, thromboxane B2
To assess pantethine on lipoprotein(a) and cardiovascular risk in diabetic patients
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To assess pantethine on lipoprotein(a) and cardiovascular risk in diabetic patients
Dose
1200 mg/day pantethine
Participants
65 type 2 diabetes patients with dyslipidaemia
Duration
6 months
Results
Significant reduction in Lp(a) by 17.4% (p=0.01) and triglycerides by 22%. LDL oxidation reduced. HbA1c unchanged. Cardiovascular risk profile improved.
How They Measured It
Lp(a), LDL, HDL, triglycerides, HbA1c
Pediatric & Special Populations
To evaluate pantethine on lipid profiles in children with familial hypercholesterolaemia
Study Type
Randomised, double-blind, placebo-controlled
Purpose
To evaluate pantethine on lipid profiles in children with familial hypercholesterolaemia
Dose
600 mg/day pantethine
Participants
49 children with familial hypercholesterolaemia
Duration
4 months
Results
Significant reduction in LDL (11.4%) and total cholesterol (9.4%). No adverse effects. HDL unchanged. Suitable alternative to lipid-lowering drugs in children.
How They Measured It
LDL, total cholesterol, HDL, ApoB levels
To evaluate pantethine in renal disease patients with dyslipidaemia
Study Type
Randomised, placebo-controlled
Purpose
To evaluate pantethine in renal disease patients with dyslipidaemia
Dose
1200 mg/day pantethine
Participants
36 chronic renal disease patients
Duration
4 months
Results
Significant reductions in total cholesterol (13.2%) and triglycerides (24.4%) vs placebo. Kidney function markers stable. Well tolerated in renal patients.
How They Measured It
Lipid panel, kidney function markers, CoA levels
To evaluate the safety and efficacy of pantethine for dyslipidaemia management
Study Type
Systematic review
Purpose
To evaluate the safety and efficacy of pantethine for dyslipidaemia management
Dose
600-1200 mg/day
Participants
Systematic review
Duration
Various
Results
Consistent lipid-lowering effects, particularly for triglycerides and LDL. Well-tolerated with no significant adverse effects. Useful adjunct therapy especially for statin-intolerant patients.
How They Measured It
Systematic review of RCTs on lipid outcomes
Frequently Asked Questions
Common questions about Coenzyme A research
There are currently 8 peer-reviewed studies on Coenzyme A (Pantethine), involving 620 total participants. Research covers Cholesterol management, Cardiovascular health, Energy metabolism and 1 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (6 human studies), and reported outcomes.
Coenzyme A has been researched for: Cholesterol management, Cardiovascular health, Energy metabolism, Adrenal support. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 6 out of 8 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
